# Tianjin Century Kangtai Biomedical Engineering

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tianjin-century-kangtai-biomedical-engineering

- Industry: Medical Devices & Equipment
- Headquarters: Tianjin, China
- Website: www.tjsjkt.com
- Latest round: Series B (Sep 20, 2023)
- Investors on record: 5

## About

Established in 2008 and based in Tianjin, China, Tianjin Century Kangtai Biomedical Engineering operates as a medical device manufacturer that provides eye health solutions. Century Kangtai (Tianjin) Technology Development Co., Ltd. is a wholly-owned subsidiary of the company. The company is headquartered in Tianjin and its plant covers an area of 5,000 square meters. It has many awards, such as "State-level high-tech enterprises" and "State-level and Tianjin science and technology-based small and medium-sized enterprises". In July 2023, the company's product "pre-assembled hydrophobic aspheric IOL" was approved. In September 2023, it closed series B funding led by SDIC Unity Capital, with participation from Dongguan Songshan Lake Science City Development Group, Efung Capital, Jinju Capital and Xiaochi Capital.

The company uses collagen-based biomaterials to develop ophthalmic medical devices. Its products are divided into two series, which include the ophthalmic material intraocular lens (IOL) series and the biomaterial collagen sponge series, such as disposable foldable IOL infuser, hydrophilic spherical foldable IOL and ocular fixation ring.

The company will launch a diffractive multifocal IOL in 2024.

## Funding rounds

- Series B, Sep 20, 2023 — Efung Capital, Jinju Capital, SDIC Unity Capital, Hangzhou Xiaochi Private Equity Fund Management, Dongguan Songshan Lake Science City Development Group

## Investors

- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B
- Jinju Capital — Series B
- SDIC Unity Capital (https://capitalatlas.ai/funds/sdic-unity-capital) — Series B
- Hangzhou Xiaochi Private Equity Fund Management (https://capitalatlas.ai/funds/hangzhou-xiaochi-private-equity-fund-management) — Series B
- Dongguan Songshan Lake Science City Development Group — Series B